Clinical Trials Directory

Trials / Completed

CompletedNCT01534065

Barricaid EU Post Market Study for Primary Lumbar Disc Herniation

A Multi-center, Post Marketing Surveillance Study to Monitor the Safety and Performance of the Barricaid® ARD in the Treatment of Back and Radicular Pain Caused by Primary Lumbar Disc Herniation

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
45 (actual)
Sponsor
Intrinsic Therapeutics · Industry
Sex
Male
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this multi-center post marketing surveillance study is to monitor the safety and performance of the Barricaid® ARD when used to surgically reconstruct the anulus of the L1 - S1 spinal disc.

Detailed description

The purpose of this prospective, randomized, multicenter study is to demonstrate the superiority of the Barricaid® when used as an adjunct to a primary lumbar limited discectomy (as described by Spengler), to limited discectomy alone, with regard to preventing reherniation and the recurrence of pain or dysfunction. Patients, ages 21 - 75, will have, in part, a positive straight leg raise (or positive femoral stretch, as appropriate), MRI confirmation of a disc herniation, and minimum Oswestry and VAS leg scores of 40 out of 100 to qualify for this study. Additional patient criteria can be found in the inclusion/exclusion criteria section. Superiority of the Barricaid relative to limited discectomy alone will be based on a comparison of overall success rates of the Barricaid and a concurrent group (randomized) of control patients treated by primary lumbar limited discectomy at select European (approximately 15-20) sites. This study has two co-primary endpoints. Success of the study will be based on the Barricaid population achieving statistical superiority over the concurrently randomized non-implanted limited discectomy population at 2 years.

Conditions

Interventions

TypeNameDescription
DEVICEBarricaidImplanted intra-operatively during discectomy

Timeline

Start date
2009-04-01
Primary completion
2013-03-01
Completion
2013-03-01
First posted
2012-02-16
Last updated
2022-04-08

Source: ClinicalTrials.gov record NCT01534065. Inclusion in this directory is not an endorsement.

Barricaid EU Post Market Study for Primary Lumbar Disc Herniation (NCT01534065) · Clinical Trials Directory